Adam Scragg
Justin Fallon
Sudhir Agrawal
Martin Akerman
Dr. Martin Akerman is the Co-founder and CTO of Envisagenics. He is the inventor of SpliceCore®, Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and discovering new drug targets in areas of unmet need. Martin trained as a post doctorate fellow with Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. He received his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA splicing can boost functionality of the human genome and trigger diseases.
Kenny Carberry
Kenny leads business development efforts and initiatives for early-stage healthcare companies. His background covers a wide array of indications across pharma, medical devices, and digital health. In addition to his expertise in business development, Kenny has several years of experience in clinical trial operations and management. He offers a unique perspective on the clinical development lifecycle from generating a comprehensive strategy through executing a successful trial.
Christopher Rao
Christopher has 15 years of experience in clinical research, with a focus on clinical trial design and operations. As a strategist, Christopher works identifies client’s key needs early and creates tailored, targeted plans for clinical development and market success. Throughout his career, Christopher has worked closely with small-to-medium biotech and pharmaceutical oncology companies, developing novel technologies.
Ibraheem Badejo
Ibraheem (Ib) is Senior R&D Director, External Front End Innovation at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector.
From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University.
During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired.
Ib received his BA degree in chemistry from Avila University. He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending